Author:
Bonifazi Meffe Luigi,Migliaccio Silvia,Napoli Nicola,Defeudis Giuseppe
Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Lu Y, Guo C (2023) Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients. Ther Adv Drug Saf 14:20420986231178126
2. Douros A, Lix LM, Fralick M, et al. for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators (2020) Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med 173(6):417–425
3. Chowdhury T, Gousy N, Bellamkonda A, et al. (2022) Fournier’s gangrene: a coexistence or consanguinity of SGLT-2 inhibitor therapy. Cureus 14(8):e27773
4. EMA (2023) GLP-1 receptor agonists: available evidence not supporting link with thyroid cancer. News 27/10/2023
5. Noel RA, Braun DK, Patterson RE, Bloomgren GL (2009) Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 32:834–838